Metformin: Is it Always First?
Listen to George L. Bakris, MD, FAHA, FASN, Cecilia C. Low Wang, MD, FACP and Neda Rasouli, MD educate clinicians on the updates made in the 2021 ADA Standards of Care related to metformin use and considerations for when the guideline recommends considering use of SGLT-2 inhibitors and GLP-1 receptor agonists independent of A1C or metformin use.
2021 Episode 3 – Metformin: Is it Always First?
George L. Bakris, MD, FAHA, FASN is a Professor of Medicine and Director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine. He has published over 800 peer-reviewed articles and book chapters in diabetic kidney disease, hypertension, and nephropathy progression. He is the recipient of the Irvine Page-Alva Bradley Lifetime Achievement Award-American Heart Association BP Council (2019) and National Kidney Foundation of Illinois Lifetime Service Award. He serves on more than 15 editorial boards and is the current Editor-in-Chief of Am J Nephrology, Editor-in-Chief of UpToDate, Nephrology section, Section Editor of UpToDate, Hypertension Section and Associate Editor of Diabetes Care and Hypertension Res.
Cecilia C. Low Wang, MD, FACP teaches, sees patients, and does research focused on diabetes clinical care in the hospital, cardiovascular complications of diabetes, and mesenchymal stem cell therapy for chronic diabetic foot ulcer. Dr. Low Wang is on the faculty of the University of Colorado Anschutz Medical Campus School of Medicine as Professor of Medicine. She directs the Glucose Management Team at the University of Colorado Hospital and the CU Diabetes Fellowship Training Program in Aurora, Colorado. Dr. Low Wang serves on committees for the Endocrine Society and American Association of Clinical Endocrinology and is involved in clinical trials through CPC Clinical Research, an academic clinical research organization.
Neda Rasouli, MD is Professor of Medicine in the Division of Endocrinology, Metabolism and Diabetes at the University of Colorado, School of Medicine. Her special expertise is in the management of diabetes and metabolic disorders associated with obesity. Her research interests include studying the pathophysiology of insulin resistance particularly molecular mechanisms involved in chronic inflammation associated with obesity and insulin resistance. In addition, Dr. Rasouli is leading several clinical trials to investigate novel therapeutic interventions in the management of diabetes. She has served on several committees of the American Diabetes Association (ADA) including the Professional Practice Committee Standard who is responsible for the “Standards of Medical Care in Diabetes” position statement. She is currently the chair of the ADA cardiovascular disease interest group.